Experimental Inhibition of Corneal Neovascularization by Photodynamic Therapy with Verteporfin

Abstract

Photodynamic therapy with verteporfin is a safe and useful procedure to reduce experimental corneal neovascularization and can be used to inhibit angiogenesis in the cornea.

Inhibition of Corneal Neovascularization by Subconjunctival and Topical Bevacizumab and Sunitinib in a Rabbit Model

“…This approach to measurement is consistent with that described previously. 20 Two weeks after the treatment, the animals were killed. The corneas were harvested and the upper half of the cornea, which contained the new corneal vessels, was collected from each eye.…”

“…After the application of topical proparacaine hydrochloride 0.5% (Alcaine; Alcon, Fort Worth, TX), CNV was induced using a previously described procedure with slight modification. 20 In brief, three 7-0 black silk sutures were placed radially, at midstromal depth, at the 10-, 12-, and 2-o'clock positions on the corneas of the right eyes, 3 mm from the limbus, avoiding corneal perforation. Moxifloxacin (Vigamox; Alcon, Fort Worth, TX) was instilled twice a day to minimize the risk of infection after surgery.…”

Evaluation of the effects of resveratrol and bevacizumab on experimental corneal alkali burn

“…Corneal neovascularization is a clinical situation which seriously threatens the vision and may result from inflammation, infection, degeneration, ischemia, and trauma [22].…”

Antilymphangiogenic therapy to promote transplant survival and to reduce cancer metastasis: What can we learn from the eye?

“…Verteporfin is used for the treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration, pathologic myopia, choroidal haemangioma, polypoidal choroidal vasculopathy and for patients with chronic or recurrent central serous chorioretinopathy. As already mentioned, it was shown that corneal blood vessels can be regressed by the use of systemically applied Verteporfin and subsequent photodynamic therapy [95,98,99].…”